GSK reported a strong performance in Q1 19, driven mainly by the strong vaccines business. Cost management was even better, resulting in a bigger beat at the profitability level. The quarter was largely characterised by a strong Shingrix and the new respiratory drugs, and efficient cost control, although the moving parts still continue to weigh on the stock – generic erosion of Advair, increasing competition in respiratory and the battle with Gilead in HIV.
03 May 2019
Shingrix continues its winning streak
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shingrix continues its winning streak
GSK plc (GSK:LON) | 1,703 -34.1 (-0.1%) | Mkt Cap: 70,583m
- Published:
03 May 2019 -
Author:
Kamla Singh -
Pages:
3
GSK reported a strong performance in Q1 19, driven mainly by the strong vaccines business. Cost management was even better, resulting in a bigger beat at the profitability level. The quarter was largely characterised by a strong Shingrix and the new respiratory drugs, and efficient cost control, although the moving parts still continue to weigh on the stock – generic erosion of Advair, increasing competition in respiratory and the battle with Gilead in HIV.